FilingReader Intelligence
Leadman Biochemistry to acquire 70% stake in biologics firm
July 31, 2025 at 05:39 AM UTC•By FilingReader AI
Beijing Leadman Biochemistry plans to acquire up to 70% of Beijing Sincerity Bio-products via cash in a major asset restructuring.
The acquisition aims to boost Leadman's diagnostics business by adding tuberculosis diagnostic and treatment capabilities, plus vaccine operations. Funding will come from self-owned capital and bank loans.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Beijing Leadman Biochemistry publishes news
Free account required • Unsubscribe anytime